Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025 Life Science Investing
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update Life Science Investing
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting Life Science Investing
Results Presented at 2026 American Academy of Dermatology Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 Life Science Investing
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 Life Science Investing
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms Life Science Investing
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg Label Life Science Investing
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates Life Science Investing
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Life Science Investing
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update Life Science Investing
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity Life Science Investing
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
